Skip to main content
Erschienen in: Journal of Cancer Education 4/2015

01.12.2015

Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians

verfasst von: Jason Zhu, Tian Zhang, Radhika Shah, Arif H. Kamal, Michael J. Kelley

Erschienen in: Journal of Cancer Education | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Quality improvement measures are uniformly applied to all oncology providers, regardless of their roles. Little is known about differences in adherence to these measures between oncology fellows, advance practice providers (APP), and attending physicians. We investigated conformance across Quality Oncology Practice Initiative (QOPI) measures for oncology fellows, advance practice providers, and attending physicians at the Durham Veterans Affairs Medical Center (DVAMC). Using data collected from the Spring 2012 and 2013 QOPI cycles, we abstracted charts of patients and separated them based on their primary provider. Descriptive statistics and the chi-square test were calculated for each QOPI measure between fellows, advanced practice providers (APPs), and attending physicians. A total of 169 patients were reviewed. Of these, 31 patients had a fellow, 39 had an APP, and 99 had an attending as their primary oncology provider. Fellows and attending physicians performed similarly on 90 of 94 QOPI metrics. High-performing metrics included several core QOPI measures including documenting consent for chemotherapy, recommending adjuvant chemotherapy when appropriate, and prescribing serotonin antagonists when prescribing emetogenic chemotherapies. Low-performing metrics included documentation of treatment summary and taking action to address problems with emotional well-being by the second office visit. Attendings documented the plan for oral chemotherapy more often (92 vs. 63 %, P = 0.049). However, after the chart audit, we found that fellows actually documented the plan for oral chemotherapy 88 % of the time (p = 0.73). APPs and attendings performed similarly on 88 of 90 QOPI measures. The quality of oncology care tends to be similar between attendings and fellows overall; some of the significant differences do not remain significant after a second manual chart review, highlighting that the use of manual data collection for QOPI analysis is an imperfect system, and there may be significant inter-observer variability.
Literatur
1.
Zurück zum Zitat Quality Oncology Practice Initiative (QOPI) (2013) American Society of Clinical Oncology Quality Oncology Practice Initiative (QOPI) (2013) American Society of Clinical Oncology
2.
Zurück zum Zitat Neuss MN, Desch CE, McNiff KK et al (2005) A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol 23:6233–6239CrossRefPubMed Neuss MN, Desch CE, McNiff KK et al (2005) A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol 23:6233–6239CrossRefPubMed
3.
Zurück zum Zitat Coscio AM, Anguiano AN, Kuderer M, Kelley M (2008) Improving quality at university based hematology/oncology fellowship continuity clinic with the quality oncology practice initiative (QOPI), 2008 ASCO Annual Meeting Proceedings Coscio AM, Anguiano AN, Kuderer M, Kelley M (2008) Improving quality at university based hematology/oncology fellowship continuity clinic with the quality oncology practice initiative (QOPI), 2008 ASCO Annual Meeting Proceedings
4.
Zurück zum Zitat Rogart JN, Siddiqui UD, Jamidar PA et al (2008) Fellow involvement may increase adenoma detection rates during colonoscopy. Am J Gastroenterol 103:2841–2846CrossRefPubMed Rogart JN, Siddiqui UD, Jamidar PA et al (2008) Fellow involvement may increase adenoma detection rates during colonoscopy. Am J Gastroenterol 103:2841–2846CrossRefPubMed
5.
Zurück zum Zitat Buchner AM, Shahid MW, Heckman MG et al (2011) Trainee participation is associated with increased small adenoma detection. Gastrointest Endosc 73:1223–1231CrossRefPubMed Buchner AM, Shahid MW, Heckman MG et al (2011) Trainee participation is associated with increased small adenoma detection. Gastrointest Endosc 73:1223–1231CrossRefPubMed
6.
Zurück zum Zitat Velikova G, Booth L, Smith AB et al (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22:714–724CrossRefPubMed Velikova G, Booth L, Smith AB et al (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22:714–724CrossRefPubMed
7.
Zurück zum Zitat Warner JL, Anick P, Drews RE (2013) Physician inter-annotator agreement in the Quality Oncology Practice Initiative manual abstraction task. J Oncol Pract 9:e96–e102PubMedCentralCrossRefPubMed Warner JL, Anick P, Drews RE (2013) Physician inter-annotator agreement in the Quality Oncology Practice Initiative manual abstraction task. J Oncol Pract 9:e96–e102PubMedCentralCrossRefPubMed
Metadaten
Titel
Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians
verfasst von
Jason Zhu
Tian Zhang
Radhika Shah
Arif H. Kamal
Michael J. Kelley
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 4/2015
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-015-0798-z

Weitere Artikel der Ausgabe 4/2015

Journal of Cancer Education 4/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.